Onkološki inštitut Ljubljana (OILJ)
-
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesLazaratos, Anna-Maria ...Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic ... settings, including for parenchymal brain metastases, their efficacy for patients with LM has not been studied in a randomized controlled trial. However, several single-armed prospective studies, case series and case reports have studied oral, intravenous, or intrathecally administered HER2-targeted therapy regimens for patients with HER2+ BC LM. Methods We conducted a systematic review and meta-analysis of individual patient data to evaluate the efficacy of HER2-targeted therapies in HER2+ BC LM in accordance with PRISMA guidelines. Targeted therapies evaluated were trastuzumab (intrathecal or intravenous), pertuzumab, lapatinib, neratinib, tucatinib, trastuzumab-emtansine and trastuzumab-deruxtecan. The primary endpoint was overall survival (OS), with CNS-specific progression-free survival (PFS) as a secondary endpoint. Results 7780 abstracts were screened, identifying 45 publications with 208 patients, corresponding to 275 lines of HER2-targeted therapy for BC LM which met inclusion criteria. In univariable and multivariable analyses, we observed no significant difference in OS and CNS-specific PFS between intrathecal trastuzumab compared to oral or intravenous administration of HER2-targeted therapy. Anti-HER2 monoclonal antibody-based regimens did not demonstrate superiority over HER2 tyrosine kinase inhibitors. In a cohort of 15 patients, treatment with trastuzumab-deruxtecan was associated with prolonged OS compared to other HER2-targeted therapies and compared to trastuzumab-emtansine. Conclusions The results of this meta-analysis, comprising the limited data available, suggest that intrathecal administration of HER2-targeted therapy for patients with HER2+ BC LM confers no additional benefit over oral and/or IV treatment regimens. Although the number of patients receiving trastuzumab deruxtecan in this cohort is small, this novel agent offers promise for this patient population and requires further investigation in prospective studies.Vir: The Breast. - ISSN 0960-9776 (Vol. 69, 2023, str. 451-468)Vrsta gradiva - članek, sestavni del ; neleposlovje za odrasleLeto - 2023Jezik - angleškiCOBISS.SI-ID - 151478531
Avtor
Lazaratos, Anna-Maria |
Maritan, Sarah M. |
Quaiattini, Andrea |
Ratoša, Ivica |
Ferraro, Emanuela |
Griguolo, Gaia |
Guarneri, Valentina |
Pellerino, Alessia |
Jacot, William |
Dobnikar, Nika, zdravnica
Teme
rak dojke |
leptomeningealne metastaze |
napredovali rak |
breast cancer |
leptomeningeal metastases |
advanced cancer
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Lazaratos, Anna-Maria | ![]() |
Maritan, Sarah M. | ![]() |
Quaiattini, Andrea | ![]() |
Ratoša, Ivica | 34883 |
Ferraro, Emanuela | ![]() |
Griguolo, Gaia | ![]() |
Guarneri, Valentina | ![]() |
Pellerino, Alessia | ![]() |
Jacot, William | ![]() |
Dobnikar, Nika, zdravnica | ![]() |
Vir: Osebne bibliografije
in: SICRIS
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Naslov za dostavo:
Med podatki člana manjka naslov.
Storitev za pridobivanje naslova trenutno ni dostopna, prosimo, poskusite še enkrat.
S klikom na gumb "V redu" boste potrdili zgoraj izbrano prevzemno mesto in dokončali postopek rezervacije.
S klikom na gumb "V redu" boste potrdili zgoraj izbrano prevzemno mesto in naslov za dostavo ter dokončali postopek rezervacije.
S klikom na gumb "V redu" boste potrdili zgoraj izbrani naslov za dostavo in dokončali postopek rezervacije.
Obvestilo
Trenutno je storitev za avtomatsko prijavo in rezervacijo nedostopna. Gradivo lahko rezervirate sami na portalu Biblos ali ponovno poskusite tukaj kasneje.
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Gradivo iz matične enote je brezplačno. Če je gradivo na mesto prevzema dostavljeno iz drugih enot, lahko knjižnica to storitev zaračuna.
Mesto prevzema | Status gradiva | Rezervacija |
---|
Rezervacija v teku
Prosimo, počakajte trenutek.
Rezervacija je uspela.
Rezervacija ni uspela.
Rezervacija...
Članska izkaznica:
Mesto prevzema: